http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-11201811661T-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e6e47d218180daeaafd2711f0d811511 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
| filingDate | 2017-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb9e6d91c3919573e924eb9eabba76f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7b4420327b8624395760d3a4bff89fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f23fdcc8e17595390dc699747e5b4635 |
| publicationDate | 2019-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | SG-11201811661T-A |
| titleOfInvention | Uses of indolinone compounds |
| abstract | INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111011101 HIM 011010101101111111110111111H1111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/022771 Al 01 February 2018 (01.02.2018) WIP0 I PCT (51) International Patent Classification: CA 92130-2122 (US). JESSEN, Katayoun; C/o Oncter- A61K 31/404 (2006.01) A61K 39/395 (2006.01) nal Therapeutics, Inc., 3525 Del Mar Heights Road, #821, A61K 31/454 (2006.01) A61K 45/06 (2006.01) San Diego, CA 92130-2122 (US). BREITMEYER, James, (21) International Application Number: Bradley; C/o Oncternal Therapeutics, Inc., 3525 Del Mar PCT/US2017/043979 Heights Road, #821, San Diego, CA 92130-2122 (US). (22) International Filing Date: (74) Agent: MALLON, Joseph, J.; Knobbe Martens Olson & 26 July 2017 (26.07.2017) Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA 92614 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/368,707 29 July 2016 (29.07.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/417,572 04 November 2016 (04.11.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/422,504 15 November 2016 (15.11.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/426,107 23 November 2016 (23.11.2016) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/503,238 08 May 2017 (08.05.2017) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/534,067 18 July 2017 (18.07.2017) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: ONCTERNAL THERAPEUTICS, INC. TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. [US/US]; 3525 Del Mar Heights Road, #821, San Diego, (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, — CA 92130-2122 (US). = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: LANNUTTI, Brian; C/o Oncternal Therapeu- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = tics, Inc., 3525 Del Mar Heights Road, #821, San Diego, = (54) Title: USES OF INDOLINONE COMPOUNDS = = = = ....-s. \ = ',. ;:,.; ,••• _ _ , . N N = .. • .‘ = = = ACTIVE INHIBITED K216 • Apoowsis: = • Oneogonosis: - Anchorage - independent growth - Programmed cell death kY - 'rumors in mice - in tumor growth . Altered Gene Expression; — - Altered Gene Expression; Il - I E',232 (ohroman regulator) - 1 E2C2 t VEGF-A (soglogeneMe) -- .1 vEGF - A Il - Alternative Splicing; • Variant ISOlonns: Ir---- - Cyan D1 t$ (activates ce cycle? - Gyart Ma (stows mil cycle) IN - ARID1A-ex18l. (chrome& tegulator) - AR1D1A-ex185 (more-ormogenic) ei ei FIG. 1 0 —..... 00 1-1 N (57) : Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations _ of venetoclax and indolinone derivatives are provided. [Continued on next page] WO 2018/022771 Al IMEDIMOM0101011MERIONIONEEHMHIMEMOIMIE TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with amended claims (Art. 19(1)) |
| priorityDate | 2016-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.